spacer
home > ebr > summer 2003 > preclinical juvenile toxicity studies: will it be safe for children?
PUBLICATIONS
European Biopharmaceutical Review

Preclinical Juvenile Toxicity Studies: Will it be Safe for Children?

The last issue of EPC highlighted the growth in paediatric clinical trials and difficulties in performing studies in children. Similar gaps in study cover have become an issue in preclinical studies and it is only in recent years that any studies have focused on the potential effects of direct treatment of young animals and on possible long-term effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences

Audrey Bottomley is a UK Registered Toxicologist and the Principal Consultant Toxicologist to the Reproductive Studies Group with over 30 years' experience in reproductive and developmental toxicology. She is now primarily concerned with advising external clients and Huntingdon Life Sciences staff on the design and interpretation of reproductive studies.


David Myers is a Senior Study Director and Consultant Toxicologist within the Reproductive Studies Group. He has a PhD in age-related changes in the behaviour and brain of the ageing female mouse and is a specialist in the effects of treatments on behaviour in rodents. David is directly involved with study design management and interpretation in the developing field of behavioural testing.


Chris Willoughby is Head of the Reproductive Studies Group at Huntingdon Life Sciences and has qualifications in pharmacy and toxicology. He has worked in reproductive toxicology with Huntingdon Life Sciences since 1974 and has extensive experience managing studies of all types.

spacer
Chris Willoughby
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement